PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY
Authors:
- I. AgirrezabalIAI. Agirrezabal
- I. GaikwadIGI. Gaikwad
- L. CirilloLCL. Cirillo
- M. LothgrenMLM. Lothgren
- 1 October 2018
- journal article
- abstracts
- Published by Elsevier in Value in Health
- Vol. 21, S31-S32